Page last updated: 2024-11-07

f-chemotactic peptide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

F-chemotactic peptide: potent chemoattractant for human neutrophils [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123875
SCHEMBL ID413804
MeSH IDM0076860

Synonyms (29)

Synonym
n-formyl-nle-leu-phe-nle-tyr-lys
71901-21-8
(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-formamidohexanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoic acid
f-chemotactic peptide
f-peptide
fnle-leu-phe-nle-tyr-lys
formylnorleucyl-leucyl-phenylalanyl-norleucyl-tyrosyl-lysine
fnlelfnlryk
n-formyl hexapeptide
fnorleu-leu-phe-norleu-tyr-lys
fnlpntl
l-lysine, n(2)-(n-(n-(n-(n-(n-formyl-l-norleucyl)-l-leucyl)-l-phenylalanyl)-l-norleucyl)-l-tyrosyl)-
cho-nle-leu-phe-nle-tyr-lys
fnlelfnleyk
SCHEMBL413804
for-nle-leu-phe-nle-tyr-lys-oh
mfcd00076348
HY-P1591
CS-0045217
formyl-norleucyl-leucyl-phenylalanyl-norleucyl-tyrosyl-lysine
formyl-nle-leu-phe-nle-tyr-lys
n-formyl-nleu1-leu2-phe3-nleu4-tyr5-lys6
(3s,6s,9s,12s,15s,18s)-18-(4-aminobutyl)-9-benzyl-3,12-dibutyl-15-(4-hydroxybenzyl)-6-isobutyl-1,4,7,10,13,16-hexaoxo-2,5,8,11,14,17-hexaazanonadecan-19-oic acid
DTXSID90992602
n~2~-{8-benzyl-5,14-dibutyl-1,4,7,10,13,16-hexahydroxy-2-[(4-hydroxyphenyl)methyl]-11-(2-methylpropyl)-3,6,9,12,15-pentaazahexadeca-3,6,9,12,15-pentaen-1-ylidene}lysine
((s)-2-((s)-2-((s)-2-((s)-2-formamidohexanamido)-4-methylpentanamido)-3-phenylpropanamido)hexanoyl)-l-tyrosyl-l-lysine
MS-31530
for-nle-leu-phe-nle-tyr-lys-ohfor-nle-leu-phe-nle-tyr-lys-oh
l-lysine,n-formyl-l-norleucyl-l-leucyl-l-phenylalanyl-l-norleucyl-l-tyrosyl-

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Cells isolated in the absence of endotoxin retained the characteristics of cells in blood and exhibited similar aggregation kinetics and dose-response to formyl peptide."( Neutrophil aggregation is beta 2-integrin- and L-selectin-dependent in blood and isolated cells.
Butcher, E; Chambers, JD; Simon, SI; Sklar, LA, 1992
)
0.28
" The diacylglycerols OAG and diC8 produced biphasic dose-response curves leading to rounding up of cells at very high stimulant concentrations."( Diacylglycerols and PMA induce actin polymerization and distinct shape changes in lymphocytes: relation to fluid pinocytosis and locomotion.
Keller, HU; Niggli, V; Zimmermann, A, 1989
)
0.28
" A dose-response curve for inhibition of covalent cross-linking of the formyl peptide derivatives by unlabeled N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys correlated closely with a dose-response curve for inhibition of binding of the same formyl peptide derivatives to the receptor."( Covalent affinity labeling of the formyl peptide chemotactic receptor.
Cuatrecasas, P; Davis, J; Niedel, J, 1980
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (78)

TimeframeStudies, This Drug (%)All Drugs %
pre-199037 (47.44)18.7374
1990's28 (35.90)18.2507
2000's9 (11.54)29.6817
2010's4 (5.13)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.79 (24.57)
Research Supply Index4.38 (2.92)
Research Growth Index4.17 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other79 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]